Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
21. Januar 2025 08:30 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Ms....
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
13. Januar 2025 08:30 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a...
Microbot Medical Closes $8.6 Million Registered Direct Offering
10. Januar 2025 10:25 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under...
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
08. Januar 2025 08:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of...
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
07. Januar 2025 16:15 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under...
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
06. Januar 2025 08:00 ET
|
Microbot Medical Inc.
HINGHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 4,000,002 shares of...
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
30. Dezember 2024 08:30 ET
|
Microbot Medical Inc.
BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, concludes 2024 with the achievement of...
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
10. Dezember 2024 10:18 ET
|
Microbot Medical Inc.
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical® Inc. (Nasdaq: MBOT), developer of the...
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
10. Dezember 2024 08:00 ET
|
Microbot Medical Inc.
FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence...
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
15. Oktober 2024 08:38 ET
|
Microbot Medical Inc.
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) --...